1AD board approves next generation fibrosis treatment AD214

Wednesday, April 18, 2018 12:30 AM +00:00

1AD board approves next generation fibrosis t...0:005:56
LIVEQuality1  AudioSubtitleDownloadSpeed1  
AdAlta
Sam Cobb

AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce a significant improvement to its lead therapeutic program. AdAlta has developed and tested an improved form of AD-114 – this new molecule has been given the name AD- 214.


Leave a Comment

Your email address will not be published

WEBCAST Calendar

  • 16 Mar

    02:00

    Working Together During Coronavirus Outbreak

    CISCO SYSTEMS
  • 16 Mar

    02:00

    FYI Resources DFS highlights low capital and operating costs for kaolin and HPA project

    FYI RESOURCES LIMITED
  • 16 Mar

    02:00

    Eli Lilly CEO talks partnering with AbCellera Biologics to co-develop a coronavirus cure 14.03.2020

    ELI LILLY AND COMPANY
  • 16 Mar

    02:00

    amaysim Australia Ltd (AYS) CEO & Managing Director, Peter O’Connell 11.03.2020

    AMAYSIM AUSTRALIA LIMITED
  • 16 Mar

    02:00

    2021 Ford Mustang Mach-E: Winter Testing All-Wheel Drive | Ford 13.03.2020

    FORD MOTOR COMPANY